Effects of semaglutide: A Synthesis of Findings from 11 Studies

  1. Home
  2. Effects of semaglutide
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of semaglutide: A Synthesis of Findings from 11 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of semaglutide: A Synthesis of Findings from 11 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Semaglutide has shown promise in treating obesity and type 2 diabetes, demonstrating significant weight reduction and improvement in glycemic control across various studies. 10 , 8 , 7 , 9 , 5 , 1 , 2 . Furthermore, research suggests that semaglutide could potentially decrease the risk of cardiovascular events. 10 , 6 , 11 . These findings suggest that semaglutide may have cardioprotective benefits beyond weight loss. 4 . Importantly, semaglutide has not been associated with adverse effects on kidney function. 3 .

Benefits and Risks

Benefits Summary

Semaglutide emerges as a promising medication for the treatment of obesity and type 2 diabetes, offering potential benefits such as weight loss, improved blood sugar control, and a reduced risk of cardiovascular events. Additionally, it has shown no adverse impact on kidney function.

Risks Summary

Semaglutide can cause gastrointestinal side effects, such as nausea, vomiting, and diarrhea. Caution is advised for individuals with impaired kidney function. 3 .

Comparison of Studies

Commonalities in Studies

Multiple studies consistently demonstrate that semaglutide contributes to weight reduction and improved blood sugar control. Research also indicates that semaglutide may lower the risk of cardiovascular events.

Differences in Studies

Variations exist in the methods of semaglutide administration, the ages of participants, and the severity of diabetes across these studies. Therefore, direct comparisons between research findings can be challenging.

Consistency and Contradictions in Results

Numerous studies point toward the efficacy of semaglutide in managing obesity and type 2 diabetes. However, further investigation is warranted to solidify the cardioprotective effects of semaglutide.

Practical Application Considerations

It is crucial for semaglutide to be used under the guidance of a healthcare professional. Moreover, it is not recommended for use during pregnancy, breastfeeding, or in individuals with compromised kidney function.

Limitations of Current Research

Further research is necessary to elucidate the long-term effectiveness and safety of semaglutide. Dosage and administration methods may need to be adjusted on an individual basis.

Future Research Directions

Additional studies are needed to fully understand the long-term effects, safety, and optimal administration methods for semaglutide. Furthermore, detailed research is required to investigate the cardioprotective benefits and impact on kidney function.

Conclusion

Semaglutide holds promise as a valuable medication for the treatment of obesity and type 2 diabetes. However, continued research is essential to assess its long-term effects and safety. If you are considering semaglutide, consult with your healthcare provider.

Literature analysis of 11 papers
Positive Content
11
Neutral Content
0
Negative Content
0
Article Type
4
1
0
1
10
1.

Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials.

Author: ZhangRui, HouQin-Chuan, LiBing-Hong, DengLing, YangYu-Mei, LiTing-Xin, YaoXiao-Qin, YangLiang-Liang, LinXi-Long, LiaoYi-Qian, WangLin, LiuYu-Ping, TanJing, WanZheng-Wei, ShuaiPing

Semaglutide efficacy
Weight reduction

Semaglutide is effective for weight reduction, but the optimal dosage and frequency of administration are unclear. This study explores the effects of different semaglutide administration regimens on weight control.

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials.

Author: MannJohannes F E, HansenThomas, IdornThomas, LeiterLawrence A, MarsoSteven P, RossingPeter, SeufertJochen, TadayonSayeh, VilsbøllTina

No increased kidney risk
Reduced UACR
Reduced eGFR

Semaglutide, a medication for type 2 diabetes, was associated with initial reductions in estimated glomerular filtration rate (eGFR) that plateaued over time. Semaglutide also led to significant reductions in urinary albumin-to-creatinine ratio (UACR), suggesting a protective effect on kidney function. There was no increase in the risk of kidney adverse events with semaglutide compared to active comparators.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.

Author: KapitzaChristoph, DahlKirsten, JacobsenJacob B, AxelsenMads B, FlintAnne

Improved beta cell function
Improved glycemic control

Semaglutide significantly improved beta cell function and glycaemic control in participants with type 2 diabetes.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

[Semaglutide for the Management of type 2 Diabetes: Clinical Evidence, Cardioprotective Effects, and Guidelines].

Author: KobalavaZh D, KokhanE V

Cardioprotective properties
DM2 management

This review discusses the cardioprotective properties of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), in patients with type 2 diabetes mellitus (DM2). Semaglutide has convincingly demonstrated its ability to reduce the risk of cardiovascular complications in DM2 patients, making it a valuable therapeutic option.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : Russian

7.

Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial.

Author: McCrimmonRory J, CatarigAndrei-Mircea, FriasJuan P, LausvigNanna L, le RouxCarel W, ThielkeDesirée, LingvayIldiko

Improved body composition

Semaglutide and canagliflozin both effectively reduced body fat mass, but semaglutide showed greater reductions in visceral fat mass compared to canagliflozin.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.

Author: VermaSubodh, McGuireDarren K, BainStephen C, BhattDeepak L, LeiterLawrence A, MazerC David, Monk FriesTea, PratleyRichard E, RasmussenSøren, VrazicHrvoje, ZinmanBernard, BuseJohn B

CV benefit
Kidney benefit

Liraglutide and semaglutide, both GLP-1 RAs, were found to be beneficial for patients with type 2 diabetes and high risk of cardiovascular events regardless of their baseline BMI. While some heterogeneity was observed in the SUSTAIN 6 trial, further studies are needed to confirm these findings.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

9.

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial.

Author: IijimaTakahiro, ShibuyaMakoto, ItoYuzuru, TerauchiYasuo

Blood glucose control
Body weight control
Adverse effects

This study investigates the effects of switching glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes, focusing on the impact on blood glucose, body weight, and adverse effects.

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

10.

Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design.

Author: RyanDonna H, LingvayIldiko, ColhounHelen M, DeanfieldJohn, EmersonScott S, KahnSteven E, KushnerRobert F, MarsoSteve, PlutzkyJorge, Brown-FrandsenKirstine, GronningMarianne O L, HovinghG Kees, HolstAnders Gaarsdal, RavnHenrik, LincoffA Michael

Cardiovascular risk reduction
Weight loss

The SELECT trial is evaluating the efficacy of semaglutide 2.4 mg subcutaneously once weekly in preventing major adverse cardiovascular events in patients with established CVD and overweight or obesity but without diabetes. This is the first cardiovascular outcomes trial to evaluate the superiority in major adverse cardiovascular events reduction for an antiobesity medication in such a population.

Clinical Trial ProtocolA plan for conducting a clinical trial. It describes in detail the purpose, design, methodology, and statistical considerations of the trial, ensuring the transparency and consistency of the trial.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

11.

The Cardioprotective Effects of Semaglutide Exceed Those of Dietary Weight Loss in Mice With HFpEF.

Author: WithaarCoenraad, MeemsLaura M G, NolletEdgar E, SchoutenE Marloes, SchroederMarie A, KnudsenLotte B, NissKristoffer, MadsenChristian T, HoeglAnnabelle, MazzoniGianluca, van der VeldenJolanda, LamCarolyn S P, SilljéHerman H W, de BoerRudolf A

Improved cardiac function
Improved cardiac structure
Improved cardiometabolic profile

Semaglutide, a glucagon-like peptide-1 receptor agonist, improved cardiometabolic profile, cardiac structure, and function in a mouse model of obesity-related HFpEF. It suggests its potential as a treatment for obesity-related heart failure.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.